Fig. 1
From: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Timeline of discovery and antibody development of LAG-3, TIM-3 and TIGIT. A. LAG-3, B. TIM-3, C. TIGIT. Notes: AML: Acute Myelocytic Leukemia; AST: Advanced Solid Tumors; BC: Breast Cancer; BLCA: Bladder Cancer; BLCA: Bladder Cancer; CAR-T: Chimeric Antigen Receptor T Cell Immunotherapy; CRC: Colorectal Cancer; DLBCL: Diffuse Large B cell Lymphoma; ESCC: Esophageal Squamous Cell Carcinoma; Fap2: Fibroblast activation protein 2; FGL-1: Fibrinogen-like protein 1; Gal-9: Galectin-9; GC: GC; HCC: Hepatocellular Carcinoma; HNSCC: Head and neck squamous cell carcinoma; LCA: Lung cancer; LSECtin: Liver and lymph node sinusoidal endothelial cell C-type lectin; MDS: Myelodysplastic Syndromes; MHC-II: MHC class II; MM: Multiple Myeloma; NPC: Nasopharyngeal Carcinoma; NSCLC: Non-small Cell Lung Cancer; OV: Ovarian Cancer; PAAD: Pancreatic Cancer; RCC: Renal Cell Carcinoma; SCC: Squamous Cell Carcinoma; SCLC: Small Cell Lung Carcinoma; TNBC: Triple-Negative Breast Cancer